Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia; University of Adelaide, Adelaide, South Australia, Australia.
University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia; Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Clin Chest Med. 2023 Dec;44(4):815-828. doi: 10.1016/j.ccm.2023.06.012. Epub 2023 Aug 14.
In the treatment of nontuberculous mycobacteria (NTM) lung disease, clinicians must consider potential toxicities that may occur as a result of prolonged exposure to a multidrug antibiotic regimen. Frequent clinical and microbiological monitoring is required to assess response and guide treatment duration. This article summarizes toxicity profiles of the antibiotics that are most frequently prescribed for the treatment of NTM lung disease. The role of therapeutic drug monitoring during use of amikacin and linezolid is discussed. The available evidence to guide frequency and extent of medication monitoring during NTM treatment is provided.
在治疗非结核分枝杆菌（NTM）肺病时，临床医生必须考虑由于长期接触多种药物抗生素方案而可能发生的潜在毒性。需要频繁的临床和微生物学监测来评估反应并指导治疗持续时间。本文总结了最常用于治疗 NTM 肺病的抗生素的毒性特征。讨论了在使用阿米卡星和利奈唑胺时进行治疗药物监测的作用。提供了指导 NTM 治疗期间药物监测频率和程度的现有证据。
